title: Divalproex versus placebo for the prevention of irritability associated with fluoxetine treatment in autism spectrum disorder.
authors.forename: Evdokia
authors.initials: E
authors.lastname: Anagnostou
authors.forename: Katherine
authors.initials: K
authors.lastname: Esposito
authors.forename: Latha
authors.initials: L
authors.lastname: Soorya
authors.forename: William
authors.initials: W
authors.lastname: Chaplin
authors.forename: Stacey
authors.initials: S
authors.lastname: Wasserman
authors.forename: Eric
authors.initials: E
authors.lastname: Hollander
mesh_terms: D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects / Q000627:therapeutic use; D018692:Antimanic Agents / Q000627:therapeutic use; D001321:Autistic Disorder / Q000188:drug therapy* / Q000523:psychology; D002648:Child; D004311:Double-Blind Method; D005473:Fluoxetine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007508:Irritable Mood / Q000187:drug effects*; D010919:Placebos; D016896:Treatment Outcome; D014635:Valproic Acid / Q000627:therapeutic use*
chemical_list: D018687:Antidepressive Agents, Second-Generation; D018692:Antimanic Agents; D010919:Placebos; D005473:Fluoxetine; D014635:Valproic Acid